Novaliq and Jiangsu Hengrui received approval from the China National Medical Products Administration (NMPA) for its Heng Qin® (Perfluorohexyloctane Eye Drops) for the treatment of dry eye disease (DED) associated with Meibomian gland dysfunction (July 2025).